Vanguard Capital Management
RNAC icon

Vanguard Capital Management’s Cartesian Therapeutics RNAC Stock Holding History

Vanguard Capital Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.01M Hold
555,823
– – ﹤0.01% 3151
2026
Q2 		$5.79M Buy
555,823
+148,226
+36% +$1.1M ﹤0.01% 3066
2026
Q1 		$2.51M Buy
+407,597
New +$2.9M ﹤0.01% 3288

Other funds holding RNAC

Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Privium Fund Management
Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $149M AUM 35.54% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Vanguard Capital Management's RNAC Position: Q3 2026 in Review

Vanguard Capital Management held its Cartesian Therapeutics (RNAC) position steady in Q3 2026 at 555,823 shares worth $4.01M. The position accounts for ﹤0.01% of the portfolio, ranked #3151.

Vanguard Capital Management first reported a position in RNAC in Q1 2026 and has held it in 3 quarters since. The position peaked at $5.79M in Q2 2026. 70 funds tracked by Wall St. Rank hold RNAC as of Q3 2026.

  • Vanguard Capital Management held 555,823 shares of Cartesian Therapeutics worth $4.01M as of Q3 2026.
  • Vanguard Capital Management left its Cartesian Therapeutics share count unchanged in Q3 2026.
  • Cartesian Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3151 holding.
  • Vanguard Capital Management first reported a position in Cartesian Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Cartesian Therapeutics position peaked at $5.79M in Q2 2026.
  • 70 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.